- Posts: 507
- Thank you received: 140
1. You must be a registered website user in order to post and comment. Guests may read only.
2. Be kind and helpful, not rude and cynical.
3. Don't advertise or promote anything. You will be banned from the group.
4. Report problems to the moderators. THANK YOU!
The only recent publication I found co-authored by Dr. Kessler regards a TPO similar to Eltrombopag, but without the dietary restrictions, called Avatrombopag:momto3boys wrote: [Dr. Kessler] coordinates a lot of the research that they do at Georgetown and he was hinting at some really exciting findings and new directions in ITP management in the work that he's doing. I'm sure everyone going to the conference will hear lots of amazing things.
... Interestingly, his office is always running trials for new things, and they were one of the places that did the initial promacta trials.
The product has been spun off to a private company, which has just announced an IPO:www.bloodjournal.org/content/123/25/3887
A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia
James B. Bussel, David J. Kuter, Louis M. Aledort, Craig M. Kessler, Adam Cuker, Kelly B. Pendergrass, Shande Tang and Joe McIntosh
Blood 2014 123:3887-3894; doi: doi.org/10.1182/blood-2013-07-514398
Key Points
Once-daily oral avatrombopag dose-dependently raised PCs over 28 days, with stable counts maintained over a 24-week extension.
Low rates of severe AEs and study drug discontinuations due to AEs occurred despite dose increases in maintenance.
www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=773819
anti-CD40L Fc-fusion protein BMS-986004
A dimeric fusion protein composed of the C-terminus of the domain antibody (dAb) BMS2h-572-633 targeting the CD40 ligand (CD40L or CD154) linked to a modified Fc fragment of immunoglobulin G1 (IgG1), with potential immunomodulatory activity. Upon intravenous administration, the peptide moiety of anti-CD40L antibody BMS-986004 specifically targets and binds to CD40L expressed on T lymphocytes. This prevents the binding of CD40L to its cognate receptor CD40 expressed on B lymphocytes, macrophages, and dendritic cells (DCs). This prevents T-cell mediated proliferation and differentiation of B cells, and prevents the production of antibodies. By inhibiting both the production of anti-glycoprotein (GP) IIb/IIIa antibodies by B cells and GPIIb/IIIa-dependent T-cell proliferation, BMS-986004 may prevent platelet destruction and may increase platelet counts in idiopathic thrombocytopenic purpura (ITP). The direct binding of BMS-986004 to CD40L on platelets further prevents CD40L/CD40-mediated destruction by macrophages and DCs in ITP. The modified Fc domain prevents the binding of BMS-986004 to the Fc receptor FcgammaRIIA on platelets, thereby preventing FcgammaRIIA-dependent platelet activation and anti-CD40L-induced thromboembolism. CD40L, a transmembrane protein of the tumor necrosis factor (TNF) superfamily, is primarily expressed on activated T cells, but is also expressed on eosinophils, basophils, natural killer (NK) cells, mast cells, platelets and activated endothelial cells. Check for active clinical trials using this agent. (NCI Thesaurus)
The Platelet Disorder Support Association does not provide medical advice or endorse any medication, vitamins or herbs. The information contained herein is not intended nor implied to be a substitute for professional medical advice and is provided for educational purposes only. Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment, discontinuing an existing treatment and to discuss any questions you may have regarding your unique medical condition.
Platelet Disorder Support Association
8751 Brecksville Road, Suite 150, Cleveland, Ohio 44141
Phone: 1-87-PLATELET | 877-528-3538 (toll free) | or 440-746-9003
E-mail: pdsa@pdsa.org
© Copyright 1997 - 2025, Platelet Disorder Support Association. All rights reserved.
The Platelet Disorder Support Association is a 501(c)3 organization and donations are tax deductible to the fullest extent allowed by law.